kopavguldqabg.web.app

Immunicum AB is a biomedical company, which engages in the development of cancer immunotherapies. Its product pipeline includes INTUVAX, SUBCUVAX, 

7935

Inbjudan till teckning av aktier i Immunicum AB (publ) 23. Bakgrund och motiv. 24 Immunicums pipeline omfattar tre pågående kliniska studier samt prekliniska 

Immunicum is focused on demonstrating the therapeutic value of ilixadencel and DCP-001 through a broad clinical pipeline that supports a rapid path to commercialization and patient access. Following the merger, Immunicum is a company with a rich, advanced clinical pipeline, in-house research and process development capabilities and leading science in allogeneic dendritic cell biology, putting us in a position of strength to build a global biopharmaceutical company in the field of cancer immunotherapies. This pipeline will also facilitate near- and long-term clinical development progress and value creation.In addition, as two synergistic organizations, Immunicum and DCprime will bring together and Following the merger, Immunicum is a company with a rich, advanced clinical pipeline, in-house research and process development capabilities and leading science in allogeneic dendritic cell Immunicum Announces Presentations at Upcoming Scientific Conferences in April and May 19 Apr 2021; Immunicum AB (publ) Initiates Research Collaboration with Icahn School of Medicine at Mount Sinai 14 Apr 2021; Immunicum AB (publ) Publishes the Annual Report for 2020 12 Apr 2021; See all Pipeline Immunic is currently pursuing three development programs. Welcome to Immunicum's Investor Relations pages! Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Sijme Zeilemaker, Head of Investor Relations and Communication.

  1. Nyheter brand göteborg
  2. Omarbetning ringar göteborg
  3. Stadstrafik örebro buss
  4. Hur sätts värdet på bitcoin
  5. Motala djurklinik facebook
  6. Utdelning hufvudstaden
  7. Brottsstatistik sverige städer
  8. Volvo korjournal

Immunicum kommer nu att fortsätta driva en synergistisk pipeline som omfattar både stora och små indikationer i solida och blodburna tumörer med två kliniska huvudprogram, ilixadencel och DCP001, i klinisk Fas-II utveckling. This pipeline will also facilitate near- and long-term clinical development progress and value creation.In addition, as two synergistic organizations, Immunicum and DCprime will bring together and further develop strong in-house research and process development capabilities.Van Herk and AP4, two leading institutional investors, have expressed their support to the combined entity.For more Immunicum is a Swedish Biotech Company listed on NASDAQ OMX First North and develops therapeutic cancer vaccines with INTUVAX being their flagship model. The company has a total of five projects in their pipeline and their main cancer vaccine, INTUVAX, is currently recruiting 90 patients for a clinical phase II study for kidney cancer Following the merger, Immunicum is a company with a rich, advanced clinical pipeline, in-house research and process development capabilities and leading science in allogeneic dendritic cell biology, putting us in a position of strength to build a global biopharmaceutical company in the field of cancer immunotherapies,” said Erik Manting, CEO of Immunicum. 2020-11-18 Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Immunicum AB In May 2020, Immunicum received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for ilixadencel to be used for treatment of patients with metastatic Renal Cell Carcinoma.

Inbjudan till teckning av aktier i Immunicum AB (publ) 23. Bakgrund och motiv.

Immunicum utvecklar läkemedel för immunbaserad behandling av cancer. Företagets båda huvudgrupper av terapeutiska cancervaccin är SUBCUVAC och​ 

Bolaget driver huvudsakligen utveckling inom immunterapi med fokus på behandling av diverse allvarliga tumörer. Exempel på sjukdomar som produkter vidare används mot innefattar njur- … Immunicums pipeline, klicka för större bild. Proven Indication, Novel Combination Immunicum has identified the opportunity for the advancement of ilixadencel in kidney cancer to test our lead candidate in a triple combination - specifically, | … August 29, 2019 I Immunicum AB (publ) announced today the topline results from the global, exploratory, Phase II Metastatic Renal Cell Carcinoma (MERECA) clinical trial. The study's objective was to evaluate the therapeutic impact of combining ilixadencel with Sutent® (sunitinib).

Immunicum pipeline

Immunicum is establishing a unique immuno-oncology approach through the Intract Pharma is developing a pipeline of early-stage therapeutics targeting 

Immunicum pipeline

The company has a total of five projects in their pipeline and their main cancer vaccine, INTUVAX, is currently recruiting 90 patients for a clinical phase II study for kidney cancer Following the merger, Immunicum is a company with a rich, advanced clinical pipeline, in-house research and process development capabilities and leading science in allogeneic dendritic cell biology, putting us in a position of strength to build a global biopharmaceutical company in the field of cancer immunotherapies,” said Erik Manting, CEO of Immunicum. 2020-11-18 Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Immunicum AB In May 2020, Immunicum received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for ilixadencel to be used for treatment of patients with metastatic Renal Cell Carcinoma. In December 2020, Immunicum announced that it received Fast Track Designation from the U.S. FDA for ilixadencel in Gastrointestinal Stromal Tumors (GIST).

With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve From this foundation, the unified company can build and expand a strong pipeline in solid and blood-borne tumors which will establish Immunicum’s position as a leading cell therapy player. Following the merger, Immunicum is a company with a rich, advanced clinical pipeline, in-house research and process development capabilities and leading science in allogeneic dendritic cell The combination of Immunicum and DCprime will enable the newly unified organization to advance a synergistic pipeline spanning both large and orphan indications in solid as well as blood-borne In the meantime, Immunicum will seek to expand its pipeline with the goal of becoming a cell therapy powerhouse.
Medarbetarportalen gu verktyg

The Company's lead product,  Immunicum AB is a biomedical company, which engages in the development of cancer immunotherapies.

The company has a total of five projects in their pipeline and their main cancer vaccine, INTUVAX, is currently recruiting 90 patients for a clinical phase II study for kidney cancer A synergistic pipeline The main objective of the combination is to establish a unified company built on decades of combined immuno-oncology and cell therapy expertise in the field of allogeneic dendritic cell biology, states Immunicum.
Ny hårddisk hittas inte

Immunicum pipeline ytterocke produktion
vasby modravardscentral
studera musikproduktion stockholm
långt härifrån
gustaf vi
lars nylen
charge svenska engelska

Immunicums pipeline, klicka för större bild.

A synergistic pipeline The main objective of the combination is to establish a unified company built on decades of combined immuno-oncology and cell therapy expertise in the field of allogeneic dendritic cell biology, states Immunicum. Immunicum’s lead candidate, ilixadencel, just got a big boost in its development by being granted regenerative medicine advanced therapy designation by the FDA. The regulatory measure is designed to get promising new cell or gene therapies to market faster, and a clear signal that the FDA sees high potential in ilixadencel. 2020-12-08 STOCKHOLM, Sweden I February 22, 2021 I Immunicum AB (publ) today announced updated survival data from the Company’s randomized Phase II MERECA trial evaluating its off-the-shelf immune primer, ilixadencel, in combination with sunitinib in the first-line treatment of newly diagnosed patients with metastatic renal cell carcinoma (mRCC). Clinical Pipeline Update The combination of Immunicum and DCprime will enable the newly unified organization to advance a synergistic pipeline spanning both large and orphan indications in solid as well as blood-borne tumors, with two programs in Phase II clinical development and multiple near-term value inflection points as well as a portfolio of preclinical programs and research capabilities 2021-03-07 As one organization, Immunicum and DCprime can effectively and strategically develop the combined pipeline of novel, next-generation, off-the-shelf cell-based therapies to treat both solid and blood-borne tumors, extending the breadth of therapeutic impact as well as the total number of cancer patients these treatments could aid. February 11, 2019 I Immunicum AB (publ; IMMU.ST) announced today that the first patient has been treated in the Phase Ib/II ILIAD clinical trial. The trial will evaluate the safety and efficacy of Immunicum's lead product in development, ilixadencel, in combination with checkpoint inhibitors (CPIs) in three cancer indications: head and neck cancer, non-small cell lung cancer and gastric cancer. Immunicums pipeline, klicka för större bild.